Harbour BioMed announced US approval of an IND to conduct a Phase II trial of its PD-L1 candidate in patients with nasopharyngeal cancer (NPC). The US FDA also granted Orphan Drug Designation to HBM9167 for the indication. In 2018, Harbour acquired global rights (ex-China) to HBM9167 from Sichuan Kelun-Biotech in a $350 million deal. Kelun-Biotech is conducting Phase II China trials of the PD-L1 in patients with lymphoma and NPC. Harbour has R&D sites in Shanghai and Suzhou, headquarters in Boston and an antibody discovery operations in Rotterdam. More details....
Share this with colleagues:
Original Article: Harbour BioMed Approved to Start US Trials of PD-L1 in Orphan Disease